Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00057954 · ClinicalTrials.gov registry record · Phase 2
Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma
A Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00057954 is a Phase 2 study that was terminated before completion, run by Eastern Cooperative Oncology Group. The registered enrollment target is 6 participants.
The verdict
NCT00057954, a Phase 2 study, was terminated before completion, sponsored by Eastern Cooperative Oncology Group.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
RATIONALE: Photopheresis allows patient white blood cells to be treated with ultraviolet (UV) light and drugs outside the body to inactivate T cells. Pentostatin may suppress the immune system and reduce the chance of developing graft-versus-host disease (GVHD) following bone marrow transplantation. Combining photopheresis with pentostatin and total-body irradiation may be effective in killing cancer cells before bone marrow transplantation. PURPOSE: This phase II trial is studying how well giving photophoresis together with pentostatin and total-body irradiation as a reduced-intensity regimen before allogeneic bone marrow transplantation works in treating patients with relapsed non-Hodgkin's or Hodgkin's lymphoma.
Interventions
- PROCEDURE Extracorporeal Photopheresis
- DRUG Pentostatin
- PROCEDURE Allogeneic bone marrow transplantation
- RADIATION Total body irradiation (TBI)
- DRUG Cyclosporin (CSA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2005-11-09 |
| Est. Completion | 2011-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00057954
The ClinicalTrials.gov registry entry for NCT00057954 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eastern Cooperative Oncology Group, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Extracorporeal Photopheresis is the first listed.
NCT00057954 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00057954 about?
NCT00057954 is a clinical study titled "Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma". RATIONALE: Photopheresis allows patient white blood cells to be treated with ultraviolet (UV) light and drugs outside the body to inactivate T cells. Pentostatin may suppress the immune system and reduce the chance of developing graft-versus-host disease (GVHD) following bone marrow transplantation....
What is the current status of trial NCT00057954?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2005-11-09. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00057954?
The interventions under investigation include: Extracorporeal Photopheresis (PROCEDURE), Pentostatin (DRUG), Allogeneic bone marrow transplantation (PROCEDURE), Total body irradiation (TBI) (RADIATION), Cyclosporin (CSA) (DRUG).
Who is sponsoring clinical trial NCT00057954?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.